Therapeutic uses of chemokine variants

Details for Australian Patent Application No. 2004281552 (hide)

Owner Merck Serono SA

Inventors Johnson, Zoe; Shaw, Jeffrey; Proudfoot, Amanda

Agent Griffith Hack

Pub. Number AU-B-2004281552

PCT Pub. Number WO2005/037305

Priority 03078308.8 16.10.03 EP

Filing date 18 October 2004

Wipo publication date 28 April 2005

Acceptance publication date 22 October 2009

International Classifications

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

C07K 14/52 (2006.01) Peptides having more than 20 amino acids

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

9 March 2006 PCT application entered the National Phase

  PCT publication WO2005/037305 Priority application(s): WO2005/037305

25 October 2007 Assignment before Grant

  Applied Research Systems ARS Holding N.V. The application has been assigned to Laboratoires Serono SA

30 April 2009 Alteration of Name

  The name of the applicant has been altered to Merck Serono SA

22 October 2009 Application Accepted

  Published as AU-B-2004281552

18 February 2010 Standard Patent Sealed

17 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004281557-Method for strengthening a proteincontaining product and a proteincontaining product

2004281551-Compositions for controlling parasites comprising a combination of abamectin and ivermectin